CMS Finalizes Scaled-Back Medicare Drug Pricing Pilot
The Trump administration finalized the GLOBE rule, a mandatory pilot aimed at lowering Medicare prices for physician-administered drugs by benchmarking them to prices in other wealthy countries. The final version applies to only four drug companies, a steep reduction from the scope of the initial proposal, and excludes companies that already struck voluntary most-favored-nation pricing deals covering Medicaid drugs. A related mandatory pilot, GUARD, remains at the proposed-rule stage. The narrowed scope significantly limits projected savings compared to the original proposal.
State Medicaid agencies and drugmakers should track how the administration's parallel voluntary Medicaid MFN deals interact with and shape the scope of these Medicare pricing pilots.
Pharmacy
You might also like